Skip to content

Application Research of Shaoyao Gancao Decoction in Colonoscopy

Application Research of Shaoyao Gancao Decoction in Colonoscopy

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2024000791
Enrollment
Unknown
Registered
2024-12-11
Start date
2024-03-01
Completion date
Unknown
Last updated
2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colonic spasm

Interventions

Experimental group:Consume 1 liter of PEG the night before the examination, and 2 liters of PEG 5 hours before the examination, finishing within 1.5 hours. Administer Shao Yao Gan Cao Decoction orally
Control group:Consume 1 liter of PEG the night before the examination, and 2 liters of PEG 5 hours before the examination, finishing within 1.5 hours. One hour before the examination, administer the p

Sponsors

Fengxian District Hospital of Traditional Chinese Medicine Shanghai
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Patients who require a non-anesthetized colonoscopy; (2) Individuals aged between 18 and 75 years regardless of gender; (3) Volunteers who consent to participate in this clinical trial and have signed the informed consent form.

Exclusion criteria

Exclusion criteria: (1) Patients requiring or requesting painless colonoscopy; (2) Individuals who cannot tolerate standard colonoscopy; (3) Patients whose standard colonoscopy did not reach the ileocecal valve; (4) Poor bowel preparation leading to poor image quality; (5) Individuals with severe primary heart liver kidney lung or hematological diseases; (6) Individuals with allergic constitution or a history of allergy to multiple medications (more than two medications or to known components of the medication in question); (7) Patients with complications such as massive gastrointestinal bleeding perforation or gastric retention; (8) Individuals with a history of colorectal surgery; (9) Patients with melanosis coli familial adenomatous polyposis colorectal cancer inflammatory bowel disease or toxic megacolon etc.; (10) Individuals who have participated in other drug clinical trials within the last 3 months; (11) Individuals deemed unsuitable for participation in this clinical trial by the researchers.

Design outcomes

Primary

MeasureTime frame
VAS (Visual Analog Scale) pain score";antispasmodic efficacy rate;detection rate of colorectal adenomas;

Secondary

MeasureTime frame
polyp detection rate;Boston Bowel Preparation Scale (BBPS);

Countries

China

Contacts

Public ContactGao Shanqing

Fengxian District Hospital of Traditional Chinese Medicine Shanghai

gaoshanqing5@126.com13918850504

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026